Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 1/2018

01-02-2018 | Review Article

Treatment Options for Resistant Kawasaki Disease

Authors: Linny Kimly Phuong, Nigel Curtis, Peter Gowdie, Jonathan Akikusa, David Burgner

Published in: Pediatric Drugs | Issue 1/2018

Login to get access

Abstract

“Resistant” Kawasaki disease is defined by the American Heart Association as failure to respond within 36 h following the first dose of intravenous immunoglobulin. The optimal management of resistant Kawasaki disease remains uncertain, the outcomes are potentially serious, and the cost of some treatments is considerable. We review the current evidence to guide treatment of resistant Kawasaki disease. Given the relative rarity, there are few trial data, and studies tend to be small and methodologically heterogeneous, making interpretation difficult and limiting generalisability. The literature on resistant Kawasaki disease should be interpreted with reference to current expert consensus guidelines.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993;87(5):1776–80.PubMedCrossRef
4.
Kato H, Koike S, Yamamoto M, et al. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J Pediatr. 1975;86(6):892–8.PubMedCrossRef
5.
Burns JC, Shike H, Gordon JB, et al. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol. 1996;1:253.CrossRef
6.
7.
8.
Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugī = [Allergy]. 1967;16(3):178–222.
9.
Sano T, Makino N, Aoyama Y, et al. Temporal and geographical clustering of Kawasaki disease in Japan (2007–2012). Pediatr Int. 2016. doi:10.​1111/​ped.​12970.
10.
Nakamura Y, Yanagawa I, Kawasaki T. Temporal and geographical clustering of Kawasaki disease in Japan. Prog Clin Biol Res. 1987;250:19–32.PubMed
11.
Yanagawa H, Yashiro M, Nakamura Y, et al. Results of 12 nationwide epidemiological incidence surveys of Kawasaki disease in Japan. Arch Pediatr Adolesc Med. 1995;149(7):779–83.PubMedCrossRef
12.
13.
Fujita Y, Nakamura Y, Sakata K, et al. Kawasaki disease in families. Pediatrics. 1989;84(4):666.PubMed
14.
15.
Saji BT, Newburger JW, Burns JC, et al. Kawasaki disease: current understanding of the mechanism and evidence-based treatment. Springer Medicine eBooks. Springer Japan; 2017,9784431560395 4431560394.
16.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017. doi:10.​1161/​CIR.​0000000000000484​.
17.
18.
Wang C-L, Wu Y-T, Liu C-A, et al. Kawasaki disease: infection, immunity and genetics. Pediatr Infect Dis J. 2005;24(11):998–1004.PubMedCrossRef
19.
20.
21.
22.
Research Committee of the Japanese Society of Pediatric Cardiology: Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki Disease. Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). Pediatr Int. 2014;56(2):135–58. doi:10.​1111/​ped.​12317.CrossRef
23.
Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997;131(6):888–93.PubMedCrossRef
24.
Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991. doi:10.​1056/​NEJM199106063242​305.
25.
Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315(6):341–7.PubMedCrossRef
26.
Okuni M, Harada K, Yamaguchi H, et al. Intravenous gamma globulin therapy in Kawasaki disease-trial of low dose gamma globulin. Prog Clin Biol Res. 1987;250:433–9.PubMed
27.
28.
Leung DY, Cotran RS, Kurt-Jones E, et al. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet. 1989;2(8675):1298–302.PubMedCrossRef
29.
Suzuki H, Uemura S, Tone S, et al. Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1 beta by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur J Pediatr. 1996;155(4):291–6.PubMedCrossRef
30.
Arend WP, Leung DY. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev. 1994;139:71–8.PubMedCrossRef
31.
Okitsu-Negishi S, Furusawa S, Kawa Y, et al. Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1. Immunol Res. 1994;13(1):49–55.PubMedCrossRef
32.
Kobayashi N, Mori M, Kobayashi Y, et al. Intravenous gamma-globulin therapy improves hypercytokinemia in the acute phase of Kawasaki disease. Mod Rheumatol. 2004;14(6):447–52.PubMedCrossRef
33.
Wang Y, Wang W, Gong F, et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum. 2013;65(3):805–14. doi:10.​1002/​art.​37815.PubMedCrossRef
34.
35.
Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995;96(6):1057–61.PubMed
36.
Kato H, Inoue O, Akagi T. Kawasaki disease: cardiac problems and management. Pediatr Rev. 1988;9(7):209–17.PubMedCrossRef
37.
38.
39.
Shulman ST, Bass JL, Bierman F, et al. Management of Kawasaki syndrome: a consensus statement prepared by North American participants of the Third International Kawasaki Disease Symposium, Tokyo, Japan, December, 1988. Pediatr Infect Dis J. 1989;8(10):663–7.CrossRef
40.
Uehara R, Belay ED, Maddox RA, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J. 2008;27(2):155–60. doi:10.​1097/​INF.​0b013e31815922b5​.PubMed
41.
Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17(12):1144–8.PubMedCrossRef
42.
43.
Kitano N, Suzuki H, Takeuchi T, et al. Epidemiologic features and prognostic factors of coronary artery lesions associated with Kawasaki disease based on a 13-year cohort of consecutive cases identified by complete enumeration surveys in Wakayama, Japan. J Epidemiol. 2014;24(5):427–34. doi:10.​2188/​jea.​JE20140018.PubMedCrossRef
44.
45.
46.
47.
48.
Hwang JY, Lee KY, Rhim JW, et al. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease. Arch Dis Child. 2011;96(11):1088–90.PubMedCrossRef
49.
50.
Levy M, Koren G. Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. Pediatr Infect Dis J. 1990;9(2):122–6.PubMedCrossRef
51.
Joffe A, Kabani A, Jadavji T. Atypical and complicated Kawasaki disease in infants. Do we need criteria? West J Med. 1995;162(4):322–7.PubMedPubMedCentral
52.
Chuang CH, Hsiao MH, Chiu CH, et al. Kawasaki disease in infants three months of age or younger. J Microbiol Immunol Infect. 2006;39(5):387–91.PubMed
53.
54.
Chang F, Hwang B, Chen S, et al. Characteristics of Kawasaki disease in infants younger than six months of age. Pediatr Infect Dis J. 2006;25(3):241–4.PubMedCrossRef
55.
Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics. 2000;105(6):E78-E.CrossRef
56.
Han RK, Silverman ED, Newman A, et al. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med. 2000;154(7):694–9.PubMedCrossRef
57.
58.
Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008;93(2):142–6.PubMedCrossRef
59.
Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. J Cardiol. 2009;53(1):15–9.PubMedCrossRef
60.
Naoe S, Takahashi K, Masuda H, et al. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathologica Japonica. 1991;41(11):785–97.PubMed
61.
62.
63.
Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996;128(1):144–6.CrossRef
64.
Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63(2):175–80.PubMed
65.
Lo JY, Minich LL, Tani LY, et al. Coronary artery disease: factors associated with resource utilization and coronary artery dilation in refractory Kawasaki disease (from the Pediatric Health Information System Database). Am J Cardiol. 2016;118(11):1636–40. doi:10.​1016/​j.​amjcard.​2016.​08.​039.PubMedCrossRef
66.
67.
Kobayashi T, Kobayashi T, Morikawa A, et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr. 2013;163(2):521–6.PubMedCrossRef
68.
69.
Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child. 2005;90(10):1096–7.PubMedPubMedCentralCrossRef
70.
71.
Kijima Y, Kamiya T, Suzuki A, et al. A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease. Jpn Circ J. 1982;46(11):1239–42.PubMedCrossRef
72.
73.
74.
Adachi S, Sakaguchi H, Kuwahara T, et al. High regression rate of coronary aneurysms developed in patients with immune globulin-resistant Kawasaki disease treated with steroid pulse therapy. Tohoku J Exp Med. 2010;220(4):285–90.PubMedCrossRef
75.
Chen S, Dong Y, Yin Y, et al. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart. 2013;99(2):76–82.PubMedCrossRef
76.
Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol. 1990;56(1):29–36.PubMedCrossRef
77.
Aeschlimann F, Yeung R. TNF and IL-1 targeted treatment in Kawasaki disease. Curr Treat Opt Rheumatol. 2016;2(4):283–95.CrossRef
78.
79.
Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol (Baltimore, Md: 1950). 2006;176(10):6294–301.CrossRef
80.
Lin CY, Lin CC, Hwang B, et al. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr. 1992;121(6):924–6.PubMedCrossRef
81.
Furukawa S, Matsubara T, Umezawa Y, et al. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr. 1994;124(5 Pt 1):721–5.PubMedCrossRef
82.
83.
Blandizzi C, Gionchetti P, Armuzzi A, et al. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol. 2014;27(1 Suppl):1–10.PubMedCrossRef
84.
85.
Ohashi R, Fukazawa R, Watanabe M, et al. Etanercept suppresses arteritis in a murine model of Kawasaki disease: a comparative study involving different biological agents. Int J Vasc Med. 2013:1–10. doi:10.​1155/​2013/​543141.
86.
Crouch SP, Fletcher J. Effect of ingested pentoxifylline on neutrophil superoxide anion production. Infect Immun. 1992;60(11):4504–9.PubMedPubMedCentral
87.
Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988;155(3):1230–6.PubMedCrossRef
88.
Furukawa S, Matsubara T, Umezawa Y, et al. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. Eur J Pediatr. 1994;153(9):663–7.PubMedCrossRef
89.
90.
91.
92.
Weiss JE, Eberhard BA, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004;31(4):808–10.PubMed
93.
94.
Masuda H, Abe J, Oana S, et al. Abstract O.51: effects of anti-TNF-alpha antibody therapy on IVIG-resistant patients with Kawasaki disease. Circulation. 2015;131(Suppl 2):AO51.
95.
96.
97.
Mori M, Imagawa T, Hara R, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol. 2012;39(4):864–7.PubMedCrossRef
98.
99.
100.
101.
Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011;158(4):644–9.PubMedCrossRef
102.
103.
104.
105.
Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40(1):35–42.PubMedCrossRef
106.
107.
108.
Alphonse MP, Duong TT, Shumitzu C, et al. Inositol-triphosphate 3-kinase C mediates inflammasome activation and treatment response in Kawasaki disease. J Immunol (Baltimore, Md: 1950). 2016;197(9):3481–9. doi:10.​4049/​jimmunol.​1600388.
109.
110.
111.
112.
Aoyagi R, Hamada H, Sato Y, et al. Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial). BMJ Open. 2015;5(12):e009562-e. doi:10.​1136/​bmjopen-2015-009562.
113.
Tremoulet AH, Pancoast P, Franco A, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin–resistant Kawasaki disease. J Pediatr. 2012;161(3):506–12.PubMedPubMedCentralCrossRef
114.
115.
116.
Kremer JM, Lawrence DA, Hamilton R, et al. Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. RMD Open. 2016;2(1):e000287-e. doi:10.​1136/​rmdopen-2016-000287.
117.
Gerards AH, de Lathouder S, de Groot ER, et al. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford, England). 2003;42(10):1189–96.
118.
Pan S, Stamp LK, Duffull SB, et al. Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clin Pharmacokinet. 2014;53(12):1161–70. doi:10.​1007/​s40262-014-0179-5.PubMedCrossRef
119.
Dalrymple JM, Stamp LK, O’Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58(11):3299–308.PubMedCrossRef
120.
121.
Ahn SY, Kim DS. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate. Scand J Rheumatol. 2005;34(2):136–9.PubMed
122.
123.
Huang S-M, Weng K-P, Chang J-S, et al. Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study. Circ J. 2008;72(10):1583–7.PubMedCrossRef
124.
Ozawa S, Hamaoka K, Niboshi N. HMG-CoA reductase inhibitors (statins) is effective in the prevention of acute coronary arteries injury in a rabbit model for Kawasaki disease. Cardiol Young. 2006;16(S2):62–3.
125.
126.
127.
128.
Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355(6):581–92.PubMedPubMedCentralCrossRef
129.
Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479–86.PubMedPubMedCentralCrossRef
130.
131.
Lee Y, Schulte DJ, Shimada K, et al. Interleukin-1[beta] is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation. 2012;125(12):1542–50.PubMedPubMedCentralCrossRef
132.
133.
134.
135.
Maury CP, Salo E, Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med. 1988;319(25):1670–1.PubMedCrossRef
136.
137.
138.
139.
140.
141.
142.
143.
Ozen S, Bilginer Y. Chapter 17: IgA vasculitis (Henoch–Schönlein purpura), polyarteritis nodosa, granulomatous polyangiitis (Wegener granulomatosis), and other vasculitides. In: Handbook of systemic autoimmune diseases. Elsevier Science & Technology; 2016. p. 1571–5078.
144.
Morishita KA, Moorthy LN, Lubieniecka JM, et al. Early outcomes in children with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2017;69(7):1470–9. doi:10.​1002/​art.​40112.PubMedCrossRef
145.
146.
Zaitsu M, Hamasaki Y, Tashiro K, et al. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis. 2000;183(3):1101–9.CrossRef
147.
Nakatani K, Takeshita S, Tsujimoto H, et al. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol. 2001;69(2):241–7.PubMed
148.
Kanai T, Ishiwata T, Kobayashi T, et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. Circulation. 2011;124(25):2822–8.PubMedCrossRef
149.
150.
Iino M, Igarashi H, Samada K, et al. A case of Kawasaki disease in NICU. Pediatr Res. 2003;53(1):181.CrossRef
151.
152.
153.
Mori M, Imagawa T, Katakura S, et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol. 2004;14(1):43–7.PubMedCrossRef
154.
155.
Matsui M, Okuma Y, Yamanaka J, et al. Kawasaki disease refractory to standard treatments that responds to a combination of pulsed methylprednisolone and plasma exchange: cytokine profiling and literature review. Cytokine. 2015;2:339. doi:10.​1016/​j.​cyto.​2015.​02.​014.CrossRef
156.
Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr. 2004;163(4–5):263–4.PubMedCrossRef
157.
158.
159.
160.
161.
162.
De Zorzi A, Colan SD, Gauvreau K, et al. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr. 1998;2:254.CrossRef
163.
Durongpisitkul K, Soongswang J, Laohaprasitiporn D, et al. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol. 2003;24(2):145–8.PubMedCrossRef
164.
de Magalhães CMR, de Magalhães Alves NR, de Melo AV, et al. Catastrophic Kawasaki disease unresponsive to IVIG in a 3-month-old infant: a diagnostic and therapeutic challenge. Pediatr Rheumatol Online J. 2012;10(1):1–9. doi:10.​1186/​1546-0096-11-7.CrossRef
Metadata
Title
Treatment Options for Resistant Kawasaki Disease
Authors
Linny Kimly Phuong
Nigel Curtis
Peter Gowdie
Jonathan Akikusa
David Burgner
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 1/2018
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-017-0269-6

Other articles of this Issue 1/2018

Pediatric Drugs 1/2018 Go to the issue

Original Research Article

Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan

Leading Article

Pharmacological Management of Restless Legs Syndrome and Periodic Limb Movement Disorder in Children

Original Research Article

Frequency and Nature of Adverse Drug Reactions Due to Non-Prescription Drugs in Children: A Retrospective Analysis from the French Pharmacovigilance Database

Review Article

State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease

Current Opinion

Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls

Leading Article

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability